Literature DB >> 27044553

Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance.

Sunwen Chou1, Ronald J Ercolani2, E Randall Lanier3.   

Abstract

Eight in vitro selection experiments under brincidofovir pressure elicited the known cytomegalovirus DNA polymerase amino acid substitutions N408K and V812L and the novel exonuclease domain substitutions D413Y, E303D, and E303G, which conferred ganciclovir and cidofovir resistance with 6- to 11-fold resistance to brincidofovir or 17-fold when E303G was combined with V812L. The new exonuclease domain I resistance mutations selected under brincidofovir pressure add to the single instance previously reported and show the expected patterns of cross-resistance.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27044553      PMCID： PMC4879386          DOI： 10.1128/AAC.00214-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir.

Authors:  Lynne Strasfeld; Ingi Lee; Walter Tatarowicz; Stephen Villano; Sunwen Chou
Journal:  J Infect Dis       Date:  2010-07-01       Impact factor: 5.226

2.  Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.

Authors:  Scott H James; Nathan B Price; Caroll B Hartline; E Randall Lanier; Mark N Prichard
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

3.  Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet.

Authors:  Christian Gilbert; Arezki Azzi; Nathalie Goyette; Sheng-Xiang Lin; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

4.  First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246.

Authors:  D R Kaul; S Stoelben; E Cober; T Ojo; E Sandusky; P Lischka; H Zimmermann; H Rubsamen-Schaeff
Journal:  Am J Transplant       Date:  2011-05       Impact factor: 8.086

5.  Cytomegalovirus antiviral resistance: characterization of results from clinical specimens.

Authors:  S Kleiboeker; J Nutt; B Schindel; J Dannehl; J Hester
Journal:  Transpl Infect Dis       Date:  2014-06-05       Impact factor: 2.228

Review 6.  Antiviral drug resistance of human cytomegalovirus.

Authors:  Nell S Lurain; Sunwen Chou
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

7.  Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism.

Authors:  Kathy A Aldern; Stephanie L Ciesla; Kristine L Winegarden; Karl Y Hostetler
Journal:  Mol Pharmacol       Date:  2003-03       Impact factor: 4.436

8.  A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.

Authors:  T Cihlar; M D Fuller; A S Mulato; J M Cherrington
Journal:  Virology       Date:  1998-09-01       Impact factor: 3.616

9.  CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.

Authors:  Francisco M Marty; Drew J Winston; Scott D Rowley; Estil Vance; Genovefa A Papanicolaou; Kathleen M Mullane; Thomas M Brundage; Alice T Robertson; Susan Godkin; Hervé Momméja-Marin; Michael Boeckh
Journal:  N Engl J Med       Date:  2013-09-26       Impact factor: 91.245

Review 10.  Utility of the bacteriophage RB69 polymerase gp43 as a surrogate enzyme for herpesvirus orthologs.

Authors:  Nicholas Bennett; Matthias Götte
Journal:  Viruses       Date:  2013-01-08       Impact factor: 5.048
View more
  10 in total

1.  Digitoxin Suppresses Human Cytomegalovirus Replication via Na+, K+/ATPase α1 Subunit-Dependent AMP-Activated Protein Kinase and Autophagy Activation.

Authors:  Rupkatha Mukhopadhyay; Rajkumar Venkatadri; Jenny Katsnelson; Ravit Arav-Boger
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

2.  Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.

Authors:  Sunwen Chou
Journal:  Antiviral Res       Date:  2016-12-08       Impact factor: 5.970

3.  Validation and Characterization of Five Distinct Novel Inhibitors of Human Cytomegalovirus.

Authors:  Arun Kapoor; Ayan K Ghosh; Michael Forman; Xin Hu; Wenjuan Ye; Noel Southall; Juan Marugan; Robert F Keyes; Brian C Smith; David J Meyers; Marc Ferrer; Ravit Arav-Boger
Journal:  J Med Chem       Date:  2020-03-27       Impact factor: 7.446

4.  Antiviral Drugs Against Herpesviruses.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Inhibition of Cytomegalovirus Replication with Extended-Half-Life Synthetic Ozonides.

Authors:  Yiping Wang; Rupkatha Mukhopadhyay; Sujayita Roy; Arun Kapoor; Yu-Pin Su; Susan A Charman; Gong Chen; Jianbo Wu; Xiaofang Wang; Jonathan L Vennerstrom; Ravit Arav-Boger
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

6.  Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility.

Authors:  Sunwen Chou
Journal:  Antiviral Res       Date:  2021-09-21       Impact factor: 5.970

7.  The Synthesis and Anti-Cytomegalovirus Activity of Piperidine-4-Carboxamides.

Authors:  Xin Guo; Ayan Kumar Ghosh; Robert F Keyes; Francis Peterson; Michael Forman; David J Meyers; Ravit Arav-Boger
Journal:  Viruses       Date:  2022-01-25       Impact factor: 5.048

Review 8.  40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?

Authors:  Anna Majewska; Beata Mlynarczyk-Bonikowska
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

9.  An MHV-68 Mutator Phenotype Mutant Virus, Confirmed by CRISPR/Cas9-Mediated Gene Editing of the Viral DNA Polymerase Gene, Shows Reduced Viral Fitness.

Authors:  Erika Trompet; Arturo Temblador; Sarah Gillemot; Dimitrios Topalis; Robert Snoeck; Graciela Andrei
Journal:  Viruses       Date:  2021-05-26       Impact factor: 5.048

Review 10.  Distribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymerase.

Authors:  D Topalis; S Gillemot; R Snoeck; G Andrei
Journal:  Nucleic Acids Res       Date:  2016-09-29       Impact factor: 16.971
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.